ann out, page-5

This is news that the market would like to see... it is a bit strange that it is note marked as price sensitive as this IS a major milestone - the beginning of sales...
30th May 2008: The Directors of KarmelSonix Ltd (ASX : KSX) are pleased to announce that the
first sale of multiple units of the PulmoTrack® have been completed in Australia. The sale of the
units to a major private sector medical group represents a significant milestone in the commercial
rollout of the Company’s products. It also represents an important step in the initial transition
from an R & D company to one focussing on the full commercialisation of the Company’s non-
invasive asthma monitoring and management tools.
Training for the PulmoTrack® units will be provided by KSX to the group’s personnel which will
enable testing of asthma patients to commence in July. This initial rollout represents an important
step in the adoption of this new approach to the monitoring and management of asthma.
Commenting on these initial sales, KSX Chairman, Mr Peter Marks said, “the sales to a substantial
private sector medical group is an important achievement in the commercial rollout of the
PulmoTrack® and augurs very well for further penetration of the market with this and subsequent
products over the coming months, and beyond.”
Following receipt of TGA approval in Australia in March 2008, and with preliminary marketing
activities underway since then, there has been substantial interest within the hospital and primary
care sectors in the capabilities of the PulmoTrack®, particularly with its unique ability to assess
asthma and wheeze without patient effort or co-operation.
Backing up the release of the PulmoTrack® will be the upcoming launch of the Nocturnal Asthma
Monitor and the WHolter – the 24 hour asthma monitor. Both products will complement the
existing features of the PulmoTrack®. KSX recently received further highly positive feedback on
the PulmoTrack® at the American Thoracic Society (ATS) Conference held in Philadelphia where
doctors, clinicians and others were highly enthusiastic about the Company’s products and their
entry into a variety of clinical settings.